A strategy for high antibody expression with low anti-drug antibodies using AAV9 vectors.

ABSTRACT:

Introduction

Use of adeno-associated virus (AAV) vectors is complicated by host immune responses that can limit transgene expression. Recent clinical trials using AAV vectors to deliver HIV broadly neutralizing antibodies (bNAbs) by intramuscular administration resulted in poor expression with anti-drug antibodies (ADA) responses against the bNAb.

Methods

Here we compared the expression of, and ADA responses against, an anti-SIV antibody ITS01 when delivered by five different AAV capsids. We first evaluated ITS01 expression from AAV vectors three different 2A peptides. Rhesus macaques were selected for the study based on preexisiting neutralizing antibodies by evaluating serum samples in a neutralization assay against the five capsids used in the study. Macaques were intramu

SUBMITTER: Davis-Gardner ME 

PROVIDER: S-EPMC10161250 | biostudies-literature | 2023

REPOSITORIES: biostudies-literature